Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanwei Xing

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 2, 2022
Protective effects of natural products against myocardial ischemia/reperfusion: Mitochondria-targeted therapeuticsXin Su, Mingyang Zhou, Yingjian Li, et al.
Medicine|February 18, 2016
Meta-Analysis of the Effects of Xingnaojing Injection on Consciousness DisturbanceLijun Wu, Hua Zhang, Yanwei Xing, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 29, 2021
Gut microbiota-derived short-chain fatty acids and hypertension: Mechanism and treatmentFan Yang, Hengwen Chen, Yonghong Gao, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|May 28, 2014
Qingkailing Suppresses the Activation of BV2 Microglial Cells by Inhibiting Hypoxia/Reoxygenation-Induced Inflammatory ResponsesLulu Mana, Shan Wang, Haiyan Zhu, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|December 10, 2013
Effects of wenxin keli on the action potential and L-type calcium current in rats with transverse aortic constriction-induced heart failureYu Chen, Yang Li, Lili Guo, et al.
Frontiers in Pharmacology|December 6, 2019
Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic TargetShengjie Yang, Xinye Li, Fan Yang, et al.
Current Pharmaceutical Design|January 17, 2020
A Pooled Analysis of the Prognostic Significance of Brugada Syndrome with Atrial FibrillationChao Tian, Na An, Mengchen Yuan, et al.
Current Pharmaceutical Design|September 5, 2018
Mitochondria and the Pathophysiological Mechanism of Atrial FibrillationXinye Li, Xinyu Yang, Yanda Li, et al.
Frontiers in Immunology|July 30, 2019
Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular DiseasesNa An, Yonghong Gao, Zeyu Si, et al.
Frontiers in Physiology|March 7, 2019
Meta-Analysis of Risk Stratification of SCN5A With Brugada Syndrome: Is SCN5A Always a Marker of Low Risk?Yihan Yang, Dan Hu, Frederic Sacher, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 2, 2022
Protective effects of natural products against myocardial ischemia/reperfusion: Mitochondria-targeted therapeuticsXin Su, Mingyang Zhou, Yingjian Li, et al.
Medicine|February 18, 2016
Meta-Analysis of the Effects of Xingnaojing Injection on Consciousness DisturbanceLijun Wu, Hua Zhang, Yanwei Xing, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 29, 2021
Gut microbiota-derived short-chain fatty acids and hypertension: Mechanism and treatmentFan Yang, Hengwen Chen, Yonghong Gao, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|May 28, 2014
Qingkailing Suppresses the Activation of BV2 Microglial Cells by Inhibiting Hypoxia/Reoxygenation-Induced Inflammatory ResponsesLulu Mana, Shan Wang, Haiyan Zhu, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|December 10, 2013
Effects of wenxin keli on the action potential and L-type calcium current in rats with transverse aortic constriction-induced heart failureYu Chen, Yang Li, Lili Guo, et al.
Frontiers in Pharmacology|December 6, 2019
Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic TargetShengjie Yang, Xinye Li, Fan Yang, et al.
Current Pharmaceutical Design|January 17, 2020
A Pooled Analysis of the Prognostic Significance of Brugada Syndrome with Atrial FibrillationChao Tian, Na An, Mengchen Yuan, et al.
Current Pharmaceutical Design|September 5, 2018
Mitochondria and the Pathophysiological Mechanism of Atrial FibrillationXinye Li, Xinyu Yang, Yanda Li, et al.
Frontiers in Immunology|July 30, 2019
Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular DiseasesNa An, Yonghong Gao, Zeyu Si, et al.
Frontiers in Physiology|March 7, 2019
Meta-Analysis of Risk Stratification of SCN5A With Brugada Syndrome: Is SCN5A Always a Marker of Low Risk?Yihan Yang, Dan Hu, Frederic Sacher, et al.
Pageof 11